Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.
[EX A]: Eli Lilly drops inhaled insulin program.

[EX Q]: Even before the new figures, the official British death toll was the fifth-highest globally and a senior scientific adviser to the government has said the country risks becoming the worst-hit in Europe. The Office for National Statistics (ONS) said 5,979 people in England had died by April 3 with COVID-19, the respiratory disease caused by the virus, mentioned on their death certificates - 15% more than numbers published by the health service. “I am not remotely surprised there would be an undercounting,” Bill Hanage, associate professor of epidemiology at Harvard’s T.H. Chan School of Public Health, told Reuters. “The UK hospital death toll that you are seeing - the one on the news each night - is a composite of things that have been trickling in over a period of time. It is not an exact number and does not include the numbers dying in places such as nursing homes.”   The new numbers, which reflect both deaths caused primarily by COVID-19 and where it is mentioned as a factor, show how limited official data has been so far. Daily figures published by the health ministry record only COVID-19 deaths in hospitals. Public Health England Medical Director Yvonne Doyle said the government was working with the ONS to speed up the information. “We just need to be absolutely clear that the cause of death that is attributed is correct and that is what takes time on the death certificate to get right,” she said, adding the government hoped to produce more rapid data, preferably on a daily basis. Compared with the ONS figures, the daily hospital counts had understated the true death toll for England and Wales by 52% as of April 3, although this had narrowed from 70% a week earlier. Still, it raises the likelihood that the latest death toll for the UK as a whole - 12,107 as of April 13 - is in reality thousands higher when deaths outside hospitals are included. “These new figures ... clearly show the impact of COVID-19 for the first time,” said Martin Hibberd, professor of emerging infectious disease at the London School of Hygiene and Tropical Medicine. London was hit particularly hard in the week to April 3, when the ONS said nearly half (46.6%) of deaths in the capital involved COVID-19. Prime Minister Boris Johnson, who is now recuperating from COVID-19 complications that almost cost him his life, initially refrained from imposing the same stringent controls as other European leaders to counter the outbreak. But as projections showed 250,000 Britons could be lost to the virus, Johnson moved to shutter the world’s fifth-largest economy and told people to stay at home. “The UK response was fractured and it was too late, and allowed a large number of people to become infected who didn’t need to become infected,” said Hanage at Harvard. “This is the start of the pandemic, not the end, and people need to understand that.”  Hanage suggested a focus on testing, using new digital technologies to give targeted advice to the population, or even detecting the virus in sewage. Government scientists have said the United Kingdom will do well if it manages to keep the coronavirus death toll below 20,000. Italy has reported a death toll of more than 20,000. Including Wales, some 6,235 people had died by April 3, the ONS said. Separate data from Scotland last week showed 354 deaths involved COVID-19 as of April 5. In Northern Ireland, the toll stood at 79 as of April 3. Across England and Wales, deaths mentioning COVID-19 accounted for 21.2% of all deaths, compared with 4.8% in the previous week. The broader reading of total deaths showed that 16,387 people died in the week ending April 3 — the highest total since weekly death data started to be compiled in 2005.
[EX A]: UK coronavirus death toll could be far higher than previously shown.

[EX Q]: Public health officials made the plea to anyone who visited specific Austin locations that the affected resident was in between Dec. 14 and Dec. 17. The Austin American-Statesman created a map of those locations. The resident is currently not in Texas. Measles is a virus that can cause high fever, cough, runny nose and red watery eyes, according to the U.S. Centers for Disease Control and Prevention. A rash appears 3 to 5 days after the first symptoms, but other complications include pneumonia and encephalitis. Health officials first alerted people in Austin about the measles case and potential exposure on Sunday, a day after state agencies were informed by Virginia officials, said Dr. Mark Escott, the interim health authority at Austin Public Health. The person traveled to Virginia on Dec. 17. The person, whom officials are not identifying, contracted the disease while traveling in Europe from late November to early December and became sick on Dec. 14, Escott said. He noted that the person developed a rash on Dec. 17, which is the day they boarded United Airlines Flight 790 from Austin to Chicago, with a connecting flight to Virginia. The person’s measles case is the first reported in Travis County since 1999, the Statesman reported. Officials didn’t disclose if the person was vaccinated. As of July 31, Texas has had 21 reported cases of measles in 2019, according to the most recent data available on the Texas Department of State Health Services website.
[EX A]:
Austin measles case not a threat, officials warn of fevers.